Department of Internal Medicine, Asanogawa General Hospital, 83 Kosakamachi, Kanazawa 910-8621, Japan.
Department of Endocrinology and Metabolism, Kanazawa University Graduate School of Medicine, 13-1 Takaramachi, Kanazawa 920-8641, Japan.
Medicina (Kaunas). 2024 Mar 8;60(3):450. doi: 10.3390/medicina60030450.
Degludec (Deg) and glargine U300 (Gla-300) are insulin analogs with longer and smoother pharmacodynamic action than glargine U100 (Gla-100), a long-acting insulin that has been widely used for many years in type 1 and type 2 diabetes. Both improve glycemic variability (GV) and the frequency of hypoglycemia, unlike Gla-100. However, it is unclear which insulin analog affects GV and hypoglycemia better in patients with insulin-dependent type 1 diabetes. We evaluated the effects of switching from Deg to Gla-300 on the day-to-day GV and the frequency of hypoglycemia in patients with insulin-dependent type 1 diabetes treated with Deg-containing basal-bolus insulin therapy (BBT). We conducted a retrospective study on 24 patients with insulin-dependent type 1 diabetes whose treatment was switched from Deg-containing BBT to Gla-300-containing BBT. We evaluated the day-to-day GV measured as the standard deviation of fasting blood glucose levels (SD-FBG) calculated by the self-monitoring of blood glucose records, the frequency of hypoglycemia (total, severe, and nocturnal), and blood glucose levels measured as fasting plasma glucose (FPG) levels and hemoglobin A1c (HbA1c). The characteristics of the patients included in the analysis with high SD-FBG had frequent hypoglycemic events, despite the use of Deg-containing BBT. For this population, SD-FBG and the frequency of nocturnal hypoglycemia decreased after the switch from Deg to Gla-300. Despite the decrease in the frequency of nocturnal hypoglycemia, the FPG and HbA1c did not worsen by the switch. The change in the SD-FBG had a negative correlation with the SD-FBG at baseline and a positive correlation with serum albumin levels. Switching from Deg to Gla-300 improved the SD-FBG and decreased the frequency of nocturnal hypoglycemia in insulin-dependent type 1 diabetes treated with Deg-containing BBT, especially in cases with low serum albumin levels and a high GV.
地特胰岛素(Deg)和甘精胰岛素 U300(Gla-300)是胰岛素类似物,与已广泛用于 1 型和 2 型糖尿病多年的长效胰岛素甘精胰岛素 U100(Gla-100)相比,具有更长和更平稳的药效学作用。与 Gla-100 不同,这两种胰岛素类似物均能改善血糖变异性(GV)和低血糖发生频率。然而,尚不清楚哪种胰岛素类似物在依赖胰岛素的 1 型糖尿病患者中对 GV 和低血糖的影响更好。我们评估了在接受地特胰岛素联合基础-餐时胰岛素治疗(BBT)的依赖胰岛素的 1 型糖尿病患者中,从地特胰岛素转换为甘精胰岛素 U300 对日常 GV 和低血糖发生频率的影响。
我们对 24 例接受地特胰岛素联合 BBT 治疗的依赖胰岛素的 1 型糖尿病患者进行了回顾性研究,这些患者转换为甘精胰岛素 U300 联合 BBT。我们通过自我监测血糖记录计算空腹血糖水平(FPG)的标准差(SD-FBG)评估日常 GV,评估低血糖(总、严重和夜间)的发生频率,以及 FPG 水平和糖化血红蛋白(HbA1c)。
分析中纳入的患者特征为尽管使用地特胰岛素联合 BBT,仍存在高 SD-FBG 和频繁低血糖事件。对于这部分人群,从地特胰岛素转换为甘精胰岛素 U300 后,SD-FBG 和夜间低血糖发生频率降低。尽管夜间低血糖发生频率降低,但 FPG 和 HbA1c 并未因转换而恶化。SD-FBG 的变化与基线时的 SD-FBG 呈负相关,与血清白蛋白水平呈正相关。
从地特胰岛素转换为甘精胰岛素 U300 改善了接受地特胰岛素联合 BBT 治疗的依赖胰岛素的 1 型糖尿病患者的 SD-FBG,并降低了夜间低血糖的发生频率,尤其是在血清白蛋白水平较低和 GV 较高的患者中。